HomepageNZM2 • ETR
add
Novozymes
Vorige slotkoers
€ 49,97
Dag-range
€ 50,66 - € 50,96
Jaar-range
€ 46,74 - € 57,24
Beurswaarde
157,62 mld. DKK
Gem. volume
498,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
CPH
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (DKK) | 2022info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 17,55 mld. | 17,40% |
Bedrijfskosten | 5,11 mld. | 7,69% |
Netto inkomsten | 3,68 mld. | 16,85% |
Netto winstmarge | 20,94 | -0,48% |
Winst per aandeel | — | — |
EBITDA | 5,72 mld. | 13,04% |
Effectief belastingtarief | 19,10% | — |
Balans
Totale activa
Totale passiva
| (DKK) | 2022info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 1,04 mld. | 8,10% |
Totale activa | 27,98 mld. | 12,99% |
Totale passiva | 13,76 mld. | 9,51% |
Totaal aandelenvermogen | 14,23 mld. | — |
Uitstaande aandelen | 276,60 mln. | — |
Koers-boekwaardeverhouding | 1,00 | — |
Rendement op activa | 10,62% | — |
Rendement op kapitaal | 14,11% | — |
Kasstroom
Nettomutatie in liquide middelen
| (DKK) | 2022info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 3,68 mld. | 16,85% |
Operationele kasstroom | 4,01 mld. | -1,38% |
Kasstroom uit beleggingen | -2,67 mld. | 2,73% |
Kasstroom uit financiering | -1,25 mld. | 21,19% |
Nettomutatie in liquide middelen | 78,00 mln. | 135,78% |
Vrije kasstroom | 574,88 mln. | -70,94% |
Over
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024.
Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange. Wikipedia
CEO
Opgericht
2000
Website
Werknemers
11.098
